ED-71, a vitamin D analog, is a more potent inhibitor of bone resorption than alfacalcidol in an estrogen-deficient rat model of osteoporosis

Bone

Volumn 30, Issue 4, 2002, Pages 582-588

  Uchiyama, Y ^a   HiguchI, Y ^a   Takeda, S ^a   Masaki, T ^a   Shira ishi, A ^a   Sato, K ^a   Kubodera, N ^a   Ikeda, K ^b   Ogata, E ^c  

^a CHUGAI PHARMACEUTICAL CO LTD   (Japan)

^b NATIONAL CENTER FOR GERIATRICS AND GERONTOLOGY   (Japan)

^c CANCER INSTITUTE HOSPITAL   (Japan)

Author keywords

Active vitamin D; Bone formation; Bone resorption; Calcium; Estrogen deficiency; Osteoporosis; Parathyroid hormone (PTH)

Indexed keywords

2BETA (3 HYDROXYPROPOXY)CALCITRIOL; ALFACALCIDOL; CALCITRIOL; CALCIUM; ESTROGEN; PARATHYROID HORMONE;

ANALYTICAL PARAMETERS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOCHEMISTRY; BONE DENSITY; BONE DEVELOPMENT; BONE MASS; BONE MINERAL; BONE REMODELING; CALCIUM ABSORPTION; CALCIUM EXCRETION; CALCIUM METABOLISM; CALCIUM URINE LEVEL; CONTROLLED STUDY; DISEASE MODEL; DRUG EFFECT; DRUG POTENCY; ESTROGEN DEFICIENCY; FEMALE; HISTOLOGY; HORMONE METABOLISM; INHIBITION KINETICS; INTESTINE ABSORPTION; LUMBAR VERTEBRA; NONHUMAN; OSSIFICATION; OSTEOCLAST; OSTEOLYSIS; OSTEOPOROSIS; OVARIECTOMY; PARATHYROID HORMONE BLOOD LEVEL; RAT; RAT STRAIN;

ADMINISTRATION, ORAL; ANIMALS; BONE DENSITY; BONE RESORPTION; CALCITRIOL; CALCIUM; DISEASE MODELS, ANIMAL; ESTROGENS; FEMALE; HYDROXYCHOLECALCIFEROLS; OSTEOPOROSIS; OVARIECTOMY; PARATHYROID HORMONE; RATS; RATS, WISTAR;

EID: 0036210478     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/S8756-3282(02)00682-8     Document Type: Article

References (24)

1. Vitamin D analogs with low affinity for the vitamin D binding protein: Enhanced in vitro and decreased in vivo activity
2. 3
3. Vitamin D and osteoporosis
4. The effect of vitamin D on osteoblasts and osteoclasts
5. Characteristics of 22-oxacalcitriol (OCT) and 2β-(3-hydroxypropoxy)-calcitriol (ED-71)
6. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation
7. Vitamin D therapy of osteoporosis: Plain vitamin D therapy versus active vitamin D analog (D-hormone) therapy
8. Bone marrow, cytokines, and bone remodeling: Emerging insights into the pathophysiology of osteoporosis
9. 3 bearing a hydroxyalkoxy group at the 2β-position
10. 3 derivative on calcium metabolism
11. 3 on lumbar bone mineral density and vertebral fractures in patients with postmenopausal osteoporosis
12. Estrogen, cytokines, and pathogenesis of postmenopausal osteoporosis
13. Bone histomorphometry: Standardization of nomenclature, symbols, and units
14. 1,25-Dihydroxycholecalciferol: A potent stimulator of bone resorption in tissue culture
15. The role of the vitamin D endocrine system in the health and disease
16. Vitamin D and its metabolites in the management of osteoporosis
17. A microtomographic system for the non-destructive evaluation of bone architecture
18. 3 (ED-71), on bone metabolism in organ culture
19. Rationale for the advantage of alfacalcidol over native vitamin D in the treatment of osteoporosis
20. Alfacalcidol inhibits bone resorption and stimulates formation in an ovariectomized rat model of osteoporosis: Distinct actions from estrogen
21. Modulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor and ligand families
22. Effects of a synthetic vitamin D analog, ED-71, on bone dynamics and strength in cancellous and cortical bone in prednisolone-treated rats
23. 3 (ED-71), increases bone mass by stimulating the bone formation in normal and ovariectomized rats
24. Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL